

Committee on Criminal Justice

SB 736 — Controlled Substances

by Senator Brodeur

The bill amends s. 893.03, F.S., to add several nitazene derivatives, which are synthetic opioids, to the list of Schedule I controlled substances, unless specifically excepted, listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration. A person who unlawfully possesses, purchases, sells, manufactures, delivers, or brings into this state these nitazene derivatives may be subject to criminal penalties under s. 893.13, F.S., or s. 893.135, F.S.

The nitazene derivatives include any material, compound, mixture, or preparation, including its salts, isomers, esters, or ethers, and salts of isomers, esters, or ethers, whenever the existence of such salts is possible within any of the following specific chemical designations containing a benzimidazole ring with an ethylamine¹ substitution at the 1-position and a benzyl ring substitution at the 2-position structure:

- With or without substitution on the benzimidazole ring with alkyl, alkoxy, carboalkoxy, amino, nitro, or aryl groups, or halogens;
- With or without substitution at the ethylamine amino moiety with alkyl, dialkyl, acetyl, or benzyl groups, whether or not further substituted in the ring system;
- With or without inclusion of the ethylamine amino moiety in a cyclic structure;
- With or without substitution of the benzyl ring; or
- With or without replacement of the benzyl ring with an aromatic ring, including, but not limited to:
 - Butonitazene.
 - Clonitazene.
 - Etodesnitazene.
 - Etonitazene.
 - Flunitazene.
 - Isotodesnitazene.
 - Isotonitazene.
 - Metodesnitazene.
 - Metonitazene.
 - Nitazene.
 - N-Desethyl Etonitazene.
 - N-Desethyl Isotonitazene.
 - N-Piperidino Etonitazene.
 - N-Pyrrolidino Etonitazene.
 - Protonitazene.

If approved by the Governor, or allowed to become law without the Governor's signature, these provisions take effect July 1, 2023.

Vote: Senate 40-0; House 114-0